Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
Nurix Therapeutics (NASDAQ: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO, Dr. Arthur T. Sands, and CFO, Hans van Houte, will engage in a fireside chat on June 4, 2025, at 3:45 p.m. ET in New York. The presentation will be available through a live webcast on Nurix's website, with the recording remaining accessible for 30 days following the event.
Nurix Therapeutics (NASDAQ: NRIX), un'azienda biofarmaceutica in fase clinica specializzata in farmaci per la degradazione mirata delle proteine, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il CEO della società, Dr. Arthur T. Sands, e il CFO, Hans van Houte, parteciperanno a un incontro informale il 4 giugno 2025 alle 15:45 ET a New York. La presentazione sarà trasmessa in diretta streaming sul sito web di Nurix e la registrazione resterà disponibile per 30 giorni dopo l'evento.
Nurix Therapeutics (NASDAQ: NRIX), una empresa biofarmacéutica en etapa clínica especializada en medicamentos de degradación dirigida de proteínas, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El CEO de la compañía, Dr. Arthur T. Sands, y el CFO, Hans van Houte, participarán en una charla informal el 4 de junio de 2025 a las 3:45 p.m. ET en Nueva York. La presentación estará disponible mediante una transmisión en vivo en el sitio web de Nurix, y la grabación permanecerá accesible por 30 días después del evento.
Nurix Therapeutics (NASDAQ: NRIX)는 표적 단백질 분해 약물에 특화된 임상 단계 생명공학 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 CEO인 Arthur T. Sands 박사와 CFO Hans van Houte는 2025년 6월 4일 오후 3시 45분(동부시간) 뉴욕에서 진행되는 비공식 대화에 참석할 예정입니다. 발표는 Nurix 웹사이트를 통해 생중계되며, 녹화 영상은 행사 후 30일간 시청할 수 있습니다.
Nurix Therapeutics (NASDAQ : NRIX), une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments de dégradation ciblée des protéines, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le PDG de la société, le Dr Arthur T. Sands, et le directeur financier, Hans van Houte, participeront à une discussion informelle le 4 juin 2025 à 15h45 (heure de l'Est) à New York. La présentation sera diffusée en direct sur le site web de Nurix, et l'enregistrement restera accessible pendant 30 jours après l'événement.
Nurix Therapeutics (NASDAQ: NRIX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf zielgerichtete Proteinabbau-Medikamente spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Der CEO des Unternehmens, Dr. Arthur T. Sands, und der CFO, Hans van Houte, werden am 4. Juni 2025 um 15:45 Uhr ET in New York an einem Gespräch am Kamin teilnehmen. Die Präsentation wird live auf der Website von Nurix übertragen, und die Aufzeichnung ist 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, and Hans van Houte, chief financial officer of Nurix, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 3:45 p.m. ET. The conference is being held in New York, NY.
The fireside chat will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Kris Fortner
Nurix Therapeutics
Kfortner@nurixtx.com
FAQ
When is Nurix Therapeutics (NRIX) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Nurix Therapeutics (NRIX) at the Jefferies Healthcare Conference 2025?
How can investors access Nurix Therapeutics' (NRIX) presentation at the Jefferies Conference?
What is Nurix Therapeutics' (NRIX) main business focus?
